Company Insights

BDSX supplier relationships

Explore interactive graphBrowse insights index
BDSX supplier relationship map

Biodesix (BDSX): supplier map, contractual posture, and what investors should watch

Biodesix operates a diagnostics and precision‑testing business that monetizes through fee‑for‑service clinical assays and the development/licensing of in‑vitro diagnostic (IVD) assays. The company combines proprietary biomarker platforms with third‑party technologies and commercial partners to deliver assays (reagents, testing services, and regulatory submissions) while funding operations through product revenue and structured financing. For investors, the supplier and contractual footprint is as important as topline growth because key third‑party relationships are both operationally critical and materially binding to test delivery. For background research and relationship scoring, visit https://nullexposure.com/.

How Biodesix makes money and why supplier ties matter

Biodesix sells diagnostic tests and develops IVD assays that hospitals, reference labs, and oncologists use to guide therapy. Revenue derives from clinical testing fees and from commercializing validated assays; the company also enters licensing and supply arrangements to scale assay throughput. The business model is asset‑light on manufacturing but heavily dependent on licensed technologies, single‑source components, and external platform vendors, which concentrates operational risk even as it reduces capital intensity.

  • Biodesix’s scale is modest (Revenue TTM ≈ $88.5M) with negative EBITDA and significant insider ownership; the company relies on third‑party capital and debt facilities to bridge growth and R&D spending.
  • Licensing and supply agreements are a core operating lever—they accelerate market access but create dependency on counterparties for reagents, instruments, and IP rights.

Explore a supplier‑focused lens on the company at https://nullexposure.com/ to see how these relationships map to enterprise risk.

The supplier and related‑party roll call (each relationship, one‑to‑two sentences)

Below I list every relationship mention found in Biodesix’s supplier scope and summarize the business impact with source context.

  • Bio‑Rad Laboratories, Inc. (10‑K, FY2024) — Biodesix entered a non‑exclusive license and supply agreement with Bio‑Rad in August 2019 to obtain equipment and reagents used for ddPCR testing, underpinning the GeneStrat test platform. Source: Biodesix FY2024 10‑K (Supply Agreement dated August 1, 2019).
  • Oncimmune Limited (10‑K, FY2024) — Biodesix acquired relationships and IP from Oncimmune as part of an acquisition, with an IP assignment dated October 31, 2019 that governs access to the Nodify CDT test. Source: Biodesix FY2024 10‑K (IP Assignment Agreement, Oct 31, 2019).
  • Perceptive Advisors (news, FY2026) — Subsequent to quarter‑end, Biodesix amended its Senior Secured Term Loan with Perceptive Advisors to extend the maturity date and interest‑only period to November 2028. Source: StockTitan coverage of Biodesix Q4 and FY2025 results (reported March 2026).
  • Canaccord Genuity (news, FY2026) — Canaccord served as a co‑manager in the company’s underwriting syndicate historically and is referenced in coverage discussing analyst and broker relations. Source: MarketBeat instant alert summarizing broker coverage (Jan 2026 / referenced FY2026).
  • Morgan Stanley (news, FY2026) — Morgan Stanley is cited as an underwriter in historical offerings and in broker commentary tied to Biodesix’s capital markets activity. Source: MarketBeat instant alert (Jan 2026 / FY2026 references).
  • William Blair (news, FY2026) — William Blair is noted as an underwriter/co‑manager in the company’s public market transactions and broker coverage. Source: MarketBeat instant alert (Jan 2026 / FY2026 references).
  • Computershare Trust Company, N.A. (news, FY2025) — Computershare acted as transfer agent for Biodesix’s one‑for‑twenty reverse stock split effective September 15, 2025. Source: QuiverQuant summary of the reverse split announcement (FY2025).
  • Nasdaq (news, FY2025) — Nasdaq announced that Biodesix common stock continued under the BDSX symbol on a split‑adjusted basis with a new CUSIP following the reverse split. Source: QuiverQuant summary referencing Nasdaq (FY2025).
  • Bio‑Rad Laboratories (news: The Healthcare Technology Report, FY2026) — Biodesix signed an expanded partnership to develop ddPCR high‑complexity IVD assays using Bio‑Rad’s QX600 platform for oncology genomic markers. Source: The Healthcare Technology Report press coverage (reported FY2026).
  • Bio‑Rad Laboratories (news: DrugDiscoveryNews, FY2025) — Announcement of an expanded partnership where Biodesix will lead development, clinical validation, and regulatory submissions for ddPCR‑based oncology assays. Source: DrugDiscoveryNews coverage (FY2025).
  • Bio‑Rad Laboratories (news: GlobeNewswire, Oct 22, 2025 / FY2025) — GlobeNewswire press release detailed the expanded partnership to enable sensitive detection of genomic markers on Bio‑Rad’s platform. Source: GlobeNewswire press release distributed Oct 22, 2025.
  • BTIG (news, FY2026) — BTIG served as a co‑manager historically in Biodesix’s underwriting syndicate and is cited in broker consensus reports. Source: MarketBeat instant alert (Jan 2026 / FY2026 references).
  • Morgan Stanley (news, FY2025) — Historical underwriter citation in broker coverage and IPO/syndicate descriptions. Source: MarketBeat instant alert summarizing broker coverage (FY2025).
  • William Blair (news, FY2025) — Repeat mention as an underwriter/co‑manager in historical capital markets activity. Source: MarketBeat instant alert (FY2025).
  • BTIG (news, FY2025) — BTIG listed as co‑manager in the underwriting syndicate on historical transactions. Source: MarketBeat instant alert (FY2025).
  • GlobeNewswire (news, FY2025) — A press release distributed through GlobeNewswire announced the expanded Bio‑Rad partnership; one summary flagged that the press release was AI‑generated in one aggregator. Source: QuiverQuant and GlobeNewswire distribution (FY2025).
  • Canaccord Genuity (news, FY2025) — Canaccord reiterated as co‑manager/underwriter in the company’s historical offering coverage. Source: MarketBeat instant alert (FY2025).
  • Bio‑Rad Laboratories (news: GlobeNewswire Nov 3, 2025 / FY2025) — Biodesix’s third‑quarter highlights noted an expanded partnership with Bio‑Rad to develop ddPCR high‑complexity assays. Source: GlobeNewswire November 3, 2025 press release.
  • Bio‑Rad Laboratories (news: StockTitan, FY2025) — StockTitan syndication repeated the announcement of the expanded Bio‑Rad collaboration to develop ddPCR assays. Source: StockTitan news item (FY2025).
  • Bio‑Rad (10‑K, FY2024 duplicate entry) — The 10‑K reiterates the nonexclusive license and supply agreement with Bio‑Rad entered in August 2019. Source: Biodesix FY2024 10‑K.
  • Oncimmune (10‑K, FY2024 duplicate entry) — The 10‑K details agreements formed during the Oncimmune acquisition to permit provision of the Nodify CDT test. Source: Biodesix FY2024 10‑K.

What the relationships and constraints reveal about operating posture

The relationship map shows a company that outsources key technology and relies on a small set of critical partners rather than vertically integrating. Three company‑level constraints define operational posture:

  • Licensing dependence and interpretation risk: Biodesix uses non‑exclusive licenses (explicit for Bio‑Rad) and warns that contract language could be subject to differing interpretations; this is a structural commercial lever that can both accelerate product launches and create IP or financial exposure. Source: FY2024 10‑K licensing disclosures.
  • Concentration and materiality: Several disclosures show that Bio‑Rad supplies essential ddPCR equipment and reagents and that single‑source suppliers provide sample kit components—supply disruption would materially impact test delivery and revenue. Source: FY2024 10‑K materiality excerpts.
  • Maturity and contractual tenor: The company operates active licensing and supply deals and holds long‑dated facilities leases (evidence of long‑term operational commitments), indicating a moderate to high maturity of commercial operations but limited supplier redundancy. Evidence: lease term to March 31, 2035 excerpt in filings.

These are company‑level signals investors should treat as operating constraints rather than one‑off vendor notes.

Explore supplier risk assessments and comparative supplier scoring at https://nullexposure.com/.

Risks, monitoring checklist, and investor actions

Investors should prioritize monitoring these items: supplier concentration metrics (percentage of critical reagents from Bio‑Rad or single‑source vendors), contractual renewal and interpretation events (licensing disputes), debt covenant and lender amendments (Perceptive loan extension), and capital markets activity that affects liquidity (reverse split and transfer agent actions).

  • Immediate risks: Supply interruption at Bio‑Rad or single‑source kit suppliers would interrupt revenue; licensing interpretation disputes could alter future obligations.
  • Credit/financing watch: The Perceptive Advisors loan amendment extending maturity to November 2028 reduces near‑term refinancing pressure but increases the timeline for performance delivery against lender covenants. Source: StockTitan coverage of loan amendment (FY2026).
  • Governance signals: High insider ownership (≈44%) and modest institutional ownership indicate insider control dynamics that affect strategic decisions such as partnering or asset sales.

Bottom line and recommended next steps

Biodesix operates a diagnosis‑centric business with clear operational leverage to a small set of strategic suppliers—most notably Bio‑Rad—that are material to assay delivery and regulatory progress. For active investors, focus analysis on supplier concentration metrics, upcoming license milestones, and the company’s ability to validate alternative suppliers for single‑source components. For due diligence, request contract summary schedules, supply‑chain continuity plans, and a timeline for regulatory submissions tied to the Bio‑Rad collaboration.

If you want a supplier risk scorecard or to map these relationships to counterparty risk, start here: https://nullexposure.com/. For a deeper firm‑level exposure report and monitoring workflow, see https://nullexposure.com/ for subscription options and tailored research.